19 May 2013
Keywords: Pfizer, Axitinib, Kidney cancer, Renal cell carcinoma, USA, FDA
Article | 29 June 2011
The US Food and Drug Administration has accepted global drugs behemoth Pfizer’s (NYSE: PFE) filing for standard review ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 June 2011
17 May 2013
© 2013 thepharmaletter.com